All In Biotech

NDA 021747 · Boehringer Ingelheim

Combivent Respimat

Albuterol Sulfate, Ipratropium Bromide · Inhalation

Last checked: Nov 20, 2026Latest source record: Sep 27, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Oct 7, 2011

Approved uses

1

Original approval plus efficacy supplements

Registered trials

793

238 Phase 3, 24 recruiting

FAERS reports

2,765

1,506 serious, 214 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 1, 2025.

COMBIVENT RESPIMAT is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta 2 -adrenergic agonist) indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator. COMBIVENT RESPIMAT Inhalation Spray is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta 2 ‑adrenergic agonist) indicated for: Patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator (1)

Mechanism: COMBIVENT RESPIMAT: COMBIVENT RESPIMAT is a combination of the anticholinergic ipratropium bromide and the beta 2 -adrenergic agonist albuterol sulfate. The mechanisms of action described below for the individual components apply to COMBIVENT RESPIMAT. The two classes of medications (an anticholinergic and a beta 2 -adrenergic agonist) are both bronchodilators. Simultaneous administration of both an anticholinergic (ipratropium bromide) and a beta 2 -sympathomimetic (albuterol sulfate) is designed to produce a greater bronchodilator effect than when either drug is utilized alone at its...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • COMBIVENT RESPIMAT · ALBUTEROL SULFATE EQ 0.1MG BASE/INH; IPRATROPIUM BROMIDE 0.02MG/INH · SPRAY, METERED, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Albuterol" as an intervention, any sponsor and status, largest first.

All 793 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea449
  • off label use232
  • pneumonia195
  • drug ineffective171
  • fatigue170
  • cough168
  • headache151
  • death133
  • nausea132
  • pain121
  • asthma119
  • diarrhoea112

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20114
20126
201340
201489
2015151
2016216
2017176
2018225
2019183
2020236
2021178
2022283
2023220
2024276
2025267
2026215

Recalls

1 FDA enforcement reports for this application.

  • Jul 24, 2015 · Class II · Terminated

    Defective Delivery System: Inhalers do not spray properly, emitting either no spray or a short transient spray.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Combivent Respimat (Ipratropium/Albuterol Sulfate)

2024 spending

$388M

Beneficiaries

154,264

602,035 claims

Per beneficiary

$2,515

$121.11 per unit

View as table
YearSpending
2020$546,288,280
2021$520,262,761
2022$484,615,822
2023$456,397,647
2024$387,905,151

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 985 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.